pngvl3-hicd vaccine
Biologicalexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2001 (NCT00436254)
Timeline
Indications
Mechanism of action
- Epidermal growth factor receptor and ErbB2 (HER1 and HER2)Immunity, active
Epidermal growth factor receptor and ErbB2 (HER1 and HER2) immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- pngvl3-hicd vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05163223 | Phase 2 | Feb 28, 2022 | Aston Sci. Co., Ltd. |
| NCT00436254 | Phase 1 | Oct 1, 2001 | National Cancer Institute (NCI), University of Washington |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aston Sci. Co., Ltd. | For profit | 1 | 1 | 1 | 2022 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2001 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2001 |
3 organizations
Page 1 / 1